About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Stroke is a medical emergency and a leading cause of death and disability worldwide affecting millions of subjects. In this context the Neurovascular Research Laboratory was created in 2001 focused in stroke research from a basic and translational perspective, covering all stages of the disease: from prevention and treatment, to recovery.
Nowadays our team is composed by a highly motivated group of researchers including clinical and basic scientists, with group leaders involved in National and International projects with public or private research funding on biomarkers for clinical decision making in stroke, the presence of silent infarctions, the assessment of cognition and cognitive decline, developing experimental models of cerebral ischemia testing new treatments complementary to reperfusion, and developing studies on cerebral amyloid angiopathy, tissue neurorepair or post-stroke rehabilitation.
Complementary studies on vascular dementia and Alzheimer disease related to amyloid-beta protein have also been encompassed as part of our research in the last years.
PMID: 33445800 Journal: Biomedicines Year: 2021 Reference: Biomedicines. 2021 Jan 12;9(1). pii: biomedicines9010072. doi: 10.3390/biomedicines9010072. Impact factor: 6.081 Publication type: Paper in international publication Authors: Vera, Rocio, Lebrato-Hernandez, Lucia, Arenillas, Juan F, Perez-Sanchez, Soledad, Montaner, Joan, Sanchez-Quesada, Jose Luis, Hernandez-Guillamon, Mar, Cardona Portela, Pere, Martinez-Zabaleta, Maite, Tur, Silvia et al. DOI: 10.3390/biomedicines9010072
PMID: 33430636 Journal: STROKE Year: 2021 Reference: Stroke. 2021 Jan;52(2):543-551. doi: 10.1161/STROKEAHA.120.029232. Epub 2021 Jan 12. Impact factor: 7.914 Publication type: Review in international publication Authors: Montellano, Felipe A, Ungethum, Kathrin, Ramiro, Laura, Nacu, Aliona, Hellwig, Simon, Fluri, Felix, Whiteley, William N, Bustamante, Alejandro, Montaner, Joan, Heuschmann, Peter U et al. DOI: 10.1161/STROKEAHA.120.029232
PMID: 33423513 Journal: STROKE Year: 2021 Reference: Stroke. 2021 Jan;52(2):505-510. doi: 10.1161/STROKEAHA.120.032025. Epub 2021 Jan 11. Impact factor: 7.914 Publication type: Paper in international publication Authors: Garcia-Tornel, Alvaro, Deck, Matias, Muchada, Marian, Boned, Sandra, Rodriguez, Noelia, Juega, Jesus, Rodriguez-Luna, David, Pagola, Jorge, Rubiera, Marta, Hernandez-Jimenez, Macarena et al. DOI: 10.1161/STROKEAHA.120.032025
PMID: 31399342 Journal: EPILEPSY & BEHAVIOR Year: 2020 Reference: Epilepsy Behav. 2020 Mar;104(Pt B):106443. doi: 10.1016/j.yebeh.2019.106443. Epub 2019 Aug 6. Impact factor: 2.508 Publication type: Paper in international publication Authors: Turon, Marc, Abraira, Laura, Cazorla, Sonia, Fonseca, Elena, Quintana, Manuel, Toledo, Manuel, Salas-Puig, Xavier, Santamarina, Estevo et al. DOI: 10.1016/j.yebeh.2019.106443
PMID: 32248061 Journal: EPILEPSY & BEHAVIOR Year: 2020 Reference: Epilepsy Behav. 2020 May;106:107045. doi: 10.1016/j.yebeh.2020.107045. Epub 2020 Apr 2. Impact factor: 2.508 Publication type: Letter or abstract Authors: Montaner, Joan, Alvarez-Sabin, Jose, Davalos, Antoni, Castellanos, Mar, Ustrell, Xavier, Abraira, Laura, Giannini, Nicola, Santamarina, Estevo, Cazorla, Sonia, Bustamante, Alejandro et al. DOI: 10.1016/j.yebeh.2020.107045
PMID: 32205379 Journal: eNeuro Year: 2020 Reference: eNeuro. 2020 Apr 16;7(2). pii: ENEURO.0218-19.2020. doi: 10.1523/ENEURO.0218-19.2020. Print 2020 Mar/Apr. Impact factor: 3.544 Publication type: Paper in international publication Authors: Cheng, Wenwen, Siedlecki-Wullich, Dolores, Catala-Solsona, Judit, Fabregas, Cristina, Fado, Rut, Sole, Montse, Unzeta, Mercedes, Saura, Carlos A, Rodriguez-Alvarez, Jose, Minano-Molina, Alfredo J et al. DOI: 10.1523/ENEURO.0218-19.2020
PMID: 31677998 Journal: EPILEPSY & BEHAVIOR Year: 2020 Reference: Epilepsy Behav. 2020 Mar;104(Pt B):106549. doi: 10.1016/j.yebeh.2019.106549. Epub 2019 Oct 31. Impact factor: 2.508 Publication type: Paper in international publication Authors: Grau-Lopez, Laia, Jimenez, Marta, Ciurans, Jordi, Becerra, Juan Luis, Millan, Monica, Cardona, Pere, Terceno, Mikel, Zaragoza, Josep, Canovas, David, Gasull, Teresa et al. DOI: 10.1016/j.yebeh.2019.106549
For three days, the III Stroke Congress of the national RICORS-ICTUS network and a symposium focused on cerebral haemorrhage were held.
The TOUCH MSCA-COFUND doctoral training programme, led by UAB and focusing on the field of mental health, has opened its first call for applications, offering 13 doctoral positions.
The Cardiovascular Diseases and Neurovascular Diseases groups at VHIR will investigate new therapeutic strategies for heart failure, nanomedicine in stroke and the prevention of cardiovascular toxicity in the case of oncological treatments.
